[go: up one dir, main page]

KR970705415A - 세포의 시토졸내로 분자를 전달시키는 방법(transfer of molecules into the cytosol of cells) - Google Patents

세포의 시토졸내로 분자를 전달시키는 방법(transfer of molecules into the cytosol of cells) Download PDF

Info

Publication number
KR970705415A
KR970705415A KR1019970701520A KR19970701520A KR970705415A KR 970705415 A KR970705415 A KR 970705415A KR 1019970701520 A KR1019970701520 A KR 1019970701520A KR 19970701520 A KR19970701520 A KR 19970701520A KR 970705415 A KR970705415 A KR 970705415A
Authority
KR
South Korea
Prior art keywords
cytosol
compound
photosensitive compound
released
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019970701520A
Other languages
English (en)
Other versions
KR100395615B1 (ko
Inventor
크리스티안 베르그
조한 모안
키르스텐 샌드비그
Original Assignee
비다르 한손
포토큐어 에이 에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비다르 한손, 포토큐어 에이 에스 filed Critical 비다르 한손
Publication of KR970705415A publication Critical patent/KR970705415A/ko
Application granted granted Critical
Publication of KR100395615B1 publication Critical patent/KR100395615B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

본 발명은 분자가 엔도좀, 리소좀 또는 다른 세포구획부에 흡수되어 엔도좀, 리소좀 또는 다른 세포 구획막을 파괴하기 위해 감광성 화합물의 광활성을 사용하브로서 다수의 세포를 죽이지 않고 세포의 시토졸로 분자를 방출하기 위한 방법을 기술하고 있다.

Description

세포의 시토졸내로 분자를 전달시키는 방법(TRANSFER OF MOLECULES INTO THE CYTOSOL OF CELLS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. a) 함께 또는 개별적으로 결합되는, 감광성 화합물, 임의적으로 벡터 분자 및 전달될 분자를 살아있는 세포에 제공하고; b) 네세포적으로 또는 다른 방법으로 엔도좀, 리소좀 또는 세포내 막 제한 구획부로 이동시키므로서 세포가; c)엔도좀, 리소좀 또는 다른 세포내 구획 막이 파괴되어 시토졸에 도입될 분자가 시토졸내로 방출되고, 광 활성 감광성 화합물 그 자체가 대부분의 세포를 죽이지 않도록, 원하는 생존률에 기초한 다양한 량의, 감광성 화합물의 흡수 스펙트럼에 따른 적절한 파장을 갖는 광에 노출되는 것을 감광성 화합물 및 특정으로 하는,감광성 화합물 및 감광성 화합물에 의해 흡수되는 광을 사용하므로서 살아있는 세포의 시토졸로 분자를 도입시키는 방법.
  2. 제1항에 있어서, 시토졸에 방출되는 분자가 DNA, 올리고(데옥시) 뉴클레오티드, mRNA, 안티센스 DNA, 설탕, 단백질, 펩티드, 막 불투과성 약물, 다른 막불투과성 분자와 상기 언급된 분자의 공유결합적으로 또는 비-공유결합적으로 결합된 조합물을 함유하는 그룹으로부터 선택되는 방법.
  3. 제1항에 있어서, 시토졸에 방출되는 분자가 단백질 합성 활성도를 변화사키는 물질의 그룹으로부터 선택되는 방법.
  4. 제2항에 있어서, 시토졸에 방출되는 화합물이 겔로닌, 사포린,아그로스틴 또는 이들의 어떤 조합물인 방법.
  5. 제1항에 있어서, 사용된 감광성 화합물이 포르피린, 프탈로시아닌, 퍼퓨린, 염소, 벤조포르피린, 나프탈로시아닌, 양이온성 색소, 테트라사이클린 및 리소좀속약산 및 이들의 유도체를 함유하는 그룹으로부터 선택되는 방법.
  6. 제5항에 있어서, 사용된 감광성 화합물이 인접한 페닐기에 2개의 설포네이트기를 갖는 테트라페닐 포르핀(TPPS2a), 4개 설포네이트기를 갖는 메조-테트라페닐 포르핀(TPPS4) 또는 인접한 펜리고리에 2개 설포네이트기를 갖는 알루미늄 프탈로시아닌(AIPcS2a) 또는 이들의 어떤 조합물인 방법.
  7. 제1항에 있어서, 사용된 벡터 분자가 감광성 화합물의 흡수를 촉진시키는 부위-지향성 분자 도는 강화제이거나 시토졸내로 방출되는 분자인 방법.
  8. 제1항에 있어서, 생존 세포의 프랙션이 감광성 화합물의 농도와 관련하여 광 조사량을 선택하므로서 조절되는 방법.
  9. a)시토졸에 방출되는 세포성 처리-변형 화합물과 광 활성시 내세포 구획부막을 파열시키는 감광성 화합물 모두가 부착된, 엔도좀, 리소좀 또는 다른 세포내 구획부와 같은 세포내 구획부로 이동을 용이하게하는 캐리어, b) 적어도 하나의 캐리어가 시토졸에 방출되는 화합물을 부착하고 다른 유사한 또는 유사하지 않은 캐리어는 감광성 화합물에 부착되는 몇 개의 캐리어, 및 c) 시토졸에 방출되는 화합물과 감광성 화합물을 개별적으로 함께 갖는 캐리어의 혼합물로 이루어진 그룹으로부터 선택된 요소를 포함하는 것을 특징으로 하는 캐리어, 감광제 및 시토졸에 방출되는 화합물 모두를 포함하는 온혈 동물 또는 세포배지에서 종양과 다른 세포처리의 변형을 위한 조성물.
  10. 제9항에 있어서, 시토졸에 방출되는 상기 화합물이 항종양성 화합물인 조성물.
  11. 제10항에 있어서, 항종양성 화합물이 겔로닌인 조성물.
  12. 제9항에 있어서, 시토졸에 방출되는 화합물이 DNA, 올리고(데옥시) 뉴클레오티드, mRNA, 안티센스 DNA, 설탕, 단백질, 펩티드, 막 불투과성 약물, 다른 막 불투과성 분자, 상기 언급된 분자의 공유결합적으로 또는 비-공유결합적으로 결합된 조합물을 함유하는 그룹으로부터 선택되는 조성물.
  13. 제9항에 있어서, 감광성 화합물이 포르피린, 프탈로시아닌, 퍼퓨린, 염소, 벤조포르피린, 나프탈로시아닌, 양이온성 색소, 테트라사이클린, 리소좀속 약산 및이들의 유도체를 함유하는 그룹으로부터 선택된 조성물.
  14. 제11항에 있어서 , 감광성 화합물이 인접한 페닐기에 2개의 설포네이트기를 갖는 테트라페닐포르핀인 조성물.
  15. 제9항에 있어서, 캐리어가 감광성 화합물의 흡수를 촉진시키는 부위-지시 분자 또는 강화제 또는 시토졸로 방출되는 분자로부터 선택된 조성물.
  16. 감광성 화합물 및 세포 막 전달을 변형하고 특정 세포군 또는 다른 관련된 기능을 촉진하는 다른 분자를 함유하는 것을 특징으로 하는, 1항의 방법을 수행하기 위한 킷트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701520A 1994-09-08 1995-09-14 세포의시토졸내로분자를전달시키는방법 Expired - Lifetime KR100395615B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO943327A NO180167C (no) 1994-09-08 1994-09-08 Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
NO943327 1994-09-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7005142A Division KR100529967B1 (ko) 1994-09-08 1995-09-14 세포의 시토졸내로 분자를 전달시키는 조성물

Publications (2)

Publication Number Publication Date
KR970705415A true KR970705415A (ko) 1997-10-09
KR100395615B1 KR100395615B1 (ko) 2003-12-31

Family

ID=19897382

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019970701520A Expired - Lifetime KR100395615B1 (ko) 1994-09-08 1995-09-14 세포의시토졸내로분자를전달시키는방법
KR10-2003-7005142A Expired - Fee Related KR100529967B1 (ko) 1994-09-08 1995-09-14 세포의 시토졸내로 분자를 전달시키는 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2003-7005142A Expired - Fee Related KR100529967B1 (ko) 1994-09-08 1995-09-14 세포의 시토졸내로 분자를 전달시키는 조성물

Country Status (19)

Country Link
US (3) US5876989A (ko)
EP (1) EP0783323B1 (ko)
JP (1) JP4148328B2 (ko)
KR (2) KR100395615B1 (ko)
CN (1) CN1222309C (ko)
AT (1) ATE209507T1 (ko)
AU (1) AU700797B2 (ko)
BR (1) BRPI9508825B8 (ko)
CA (1) CA2199290C (ko)
CZ (1) CZ65897A3 (ko)
DE (1) DE69524238T2 (ko)
ES (1) ES2163527T3 (ko)
FI (1) FI121328B (ko)
HU (1) HU222984B1 (ko)
MX (1) MX9701676A (ko)
NO (1) NO180167C (ko)
NZ (2) NZ509519A (ko)
PT (1) PT783323E (ko)
WO (1) WO1996007432A1 (ko)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US6210356B1 (en) * 1998-08-05 2001-04-03 Ekos Corporation Ultrasound assembly for use with a catheter
ATE409005T1 (de) * 1997-03-19 2008-10-15 Lucid Inc Zellchirurgie unter benutzung konfokaler mikroskopie
US6582392B1 (en) * 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
ATE443528T1 (de) * 1998-01-05 2009-10-15 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
US6399769B1 (en) * 1998-01-20 2002-06-04 Kimberly-Clark Worldwide, Inc. Method of making sulfanatophenyl substituted porphines
GB9905911D0 (en) * 1999-03-15 1999-05-05 Photocure As Method
US7320885B1 (en) * 1999-09-09 2008-01-22 Toudai Tlo, Ltd. Method of perforating membrane and apparatus therefor
EP2364734B1 (en) * 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
BR0115795A (pt) * 2000-11-29 2003-08-12 Pci Biotech As Métodos para introduzir uma molécula no citosol de uma célula, para o tratamento ou prevenção de uma doença, distúrbio ou infecção em um paciente, para estimular uma resposta imune, célula, e, uso de uma molécula de transferência e/ou um agente fotossensibilizante
BRPI0115794B1 (pt) * 2000-11-29 2015-09-15 Pci Biotech As método para introduzir uma molécula em uma célula, composição farmacêutica, e, uso de uma molécula de transferência associada com um veículo viral e um agente fotossensibilizante ou de uma célula
US20020098472A1 (en) * 2000-11-30 2002-07-25 Erlach Julian Van Method for inserting a microdevice or a nanodevice into a body fluid stream
US20020137901A1 (en) * 2001-01-22 2002-09-26 Cavanaugh Philip Gerard Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin
US20030031655A1 (en) * 2001-02-08 2003-02-13 Sequitur, Inc. Methods of light activated release of ligands from endosomes
JP4081436B2 (ja) * 2001-06-20 2008-04-23 大日本住友製薬株式会社 核酸導入を促進させる方法
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
AU2002359576A1 (en) 2001-12-03 2003-06-17 Ekos Corporation Catheter with multiple ultrasound radiating members
US7141044B2 (en) 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
EP1572902B1 (en) * 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP2213292B2 (en) 2002-02-01 2016-06-22 Life Technologies Corporation Double-stranded oligonucleotides
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
GB0215534D0 (en) * 2002-07-04 2002-08-14 Ecole Polytech Selective photochemotherapy using oligonucleotide targeting agents
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US6921371B2 (en) * 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
US7332477B2 (en) * 2003-07-10 2008-02-19 Nitto Denko Corporation Photocleavable DNA transfer agent
DE602004026747D1 (de) * 2003-09-29 2010-06-02 Nitto Denko Corp Biologisch abbaubare polyacetale für die in-vivo-abgabe von polynucleotiden
JP4954550B2 (ja) * 2003-12-19 2012-06-20 大日本住友製薬株式会社 新規な核酸導入法
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP2985039B1 (en) * 2004-03-03 2018-08-01 ReVance Therapeutics, Inc. Topical application and transdermal delivery of botulinum toxins
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
US20060094781A1 (en) * 2004-11-04 2006-05-04 Syneron Medical Ltd. Method of treating extracellular matrix
FR2877943B1 (fr) * 2004-11-16 2008-09-05 Univ De Coimbra Nouveaux derives de porphyrine, notamment chlorines et/ou bacteriochlorine, et leurs applications en therapie photodynamique
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
KR101453963B1 (ko) 2005-03-03 2014-10-22 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
US7674452B2 (en) * 2005-03-16 2010-03-09 Nitto Denko Corporation Polymer coating of cells
BRPI0501037B8 (pt) 2005-03-18 2021-07-27 Fund De Amparo A Pesquisa Do Estado De Sao Paulo uso de crotamina e composição
BRPI0618753A2 (pt) * 2005-11-17 2011-09-13 Revance Therapeutics Inc composição para liberação transdérmica de toxina botulìnica e método de administração
WO2007109584A1 (en) * 2006-03-16 2007-09-27 University Of Washington Temperature-and ph-responsive polymer compositions
GB0613753D0 (en) * 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
AU2007333225B2 (en) * 2006-12-08 2014-06-12 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
CA2672886C (en) * 2006-12-29 2015-02-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
US9044568B2 (en) 2007-06-22 2015-06-02 Ekos Corporation Method and apparatus for treatment of intracranial hemorrhages
EP2231024A4 (en) * 2007-12-14 2015-03-18 Ekos Corp ULTRASOUND PULSE SHAPING
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
GB201208548D0 (en) * 2012-05-15 2012-06-27 Pci Biotech As Compound and method
WO2014139597A1 (en) 2013-03-15 2014-09-18 Pci Biotech As Method
EP3038619B1 (en) 2013-08-28 2023-10-04 PCI Biotech AS Compound and method for vaccination and immunisation
GB2517707B (en) 2013-08-28 2020-09-02 Pci Biotech As A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen
US10973896B2 (en) 2014-04-11 2021-04-13 Pci Biotech As Treatment or prevention of melanoma using photochemical internalization of a melanoma antigen
JP2017526371A (ja) 2014-08-28 2017-09-14 ピーシーアイ バイオテック エイエス 化合物および方法
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
US10656025B2 (en) 2015-06-10 2020-05-19 Ekos Corporation Ultrasound catheter
RU2019109682A (ru) 2016-10-14 2020-11-16 ПиСиАй БИОТЕК АС Лечение холангиокарциномы с применением tpcs-2-индуцированной фотохимической интернализации гемцитабина
GB201718631D0 (en) * 2017-11-10 2017-12-27 Pci Biotech As Method
GB201801169D0 (en) * 2018-01-24 2018-03-07 Pci Biotech As Method
EP3823668A1 (en) 2018-07-16 2021-05-26 DCPrime B.V. A combination product for use in tumor vaccination
EP3958894A1 (en) 2019-04-25 2022-03-02 DCPrime B.V. Methods of tumor vaccination
CN110711249B (zh) * 2019-09-19 2020-10-27 北京化工大学 一种溶酶体膜包覆纳米颗粒的制备方法
AU2021244937A1 (en) 2020-03-27 2022-11-03 Mendus B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN114163508B (zh) * 2020-09-11 2024-07-16 王月志 能破坏细胞的氨基酸序列及相关核苷酸序列和相关的应用
CA3196677A1 (en) 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method
KR20250075638A (ko) 2022-09-27 2025-05-28 피씨아이 바이오테크 에이에스 바이러스 벡터를 방출하는 방법
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product
GB202404168D0 (en) 2024-03-22 2024-05-08 Pci Biotech As Method

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU563827B2 (en) 1982-07-01 1987-07-23 Millipore Corp. Filtration apparatus
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4704255A (en) 1983-07-15 1987-11-03 Pandex Laboratories, Inc. Assay cartridge
US5066274A (en) * 1985-04-30 1991-11-19 Nippon Petrochemicals Company, Ltd. Tetrapyrrole therapeutic agents
US5076950A (en) 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
US4895706A (en) 1986-10-28 1990-01-23 Costar Corporation Multi-well filter strip and composite assemblies
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
HU204856B (en) 1987-08-12 1992-02-28 Orszagos Mueszaki Fejlesztesi Process for releasing cell mixtures and tissues from undesired populations and for producing monoclonal antibody - hematoporphyrin conjugates
NO891491L (no) * 1987-08-12 1989-04-11 Peter Nemeth Prosedyre for befrielse av celleblandinger og vev for uoenskede populasjoner.
GB8721108D0 (en) * 1987-09-08 1987-10-14 Salford University Of Liposomes
US5284647A (en) * 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5256532A (en) 1988-05-02 1993-10-26 Zynaxis Technologies, Inc. Methods, reagents and test kits for determination of subpopulations of biological entities
US4925736A (en) * 1988-07-06 1990-05-15 Long Island Jewish Medical Center Topical hematoporphyrin
GB8905001D0 (en) 1989-03-04 1989-04-19 Univ Leicester Screening for natural products of microbial metabolism
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5567687A (en) * 1989-03-06 1996-10-22 University Of Texas Texaphyrins and uses thereof
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5059619A (en) * 1989-06-14 1991-10-22 Quadra Logic Technologies, Inc. Stable freeze-dried polyhematoporphyrin ether/ester
DE3919873A1 (de) 1989-06-19 1990-12-20 Behringwerke Ag Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
GB8916859D0 (en) 1989-07-24 1989-09-06 Dynal As Hapten linking
GB8929297D0 (en) 1989-12-29 1990-02-28 Dynal As Method of separation
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5491068A (en) 1991-02-14 1996-02-13 Vicam, L.P. Assay method for detecting the presence of bacteria
US5179120A (en) * 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
PL165249B1 (pl) * 1991-10-29 1994-11-30 Wojskowa Akad Tech Sposób otrzymywania soli kompleksowych hematoporfiryny i jej pochodnych PL PL PL PL PL PL PL
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
AU675638B2 (en) * 1992-03-16 1997-02-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
FI944340A0 (fi) 1992-03-20 1994-09-19 Celsis Ltd Menetelmä ja laite biologisen materiaalin analysoimiseksi
JPH07506252A (ja) * 1992-04-24 1995-07-13 エス・アール・アイ・インターナシヨナル 真核細胞内でのイン・ビボ相同配列ターゲッティング
WO1994007138A1 (en) 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
DE69333550T2 (de) * 1992-11-03 2005-06-23 Gene Shears Pty. Ltd. TNF-alpha RIBOZYME UND ABBAU-RESISTENTE mRNA DERIVATIVE GEBUNDEN AN TNF-alpha Ribozyme
FR2700010B1 (fr) 1992-12-24 1995-03-17 Rocher Yves Biolog Vegetale Méthode et dispositif pour tester la réactivité de cellules à l'égard de produits.
US5374531A (en) 1993-03-22 1994-12-20 Zynaxis, Inc. Immunoassay for determination of cells
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US5491084A (en) * 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5872007A (en) * 1995-02-17 1999-02-16 Hybridon, Inc. CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer

Also Published As

Publication number Publication date
KR20040004402A (ko) 2004-01-13
AU700797B2 (en) 1999-01-14
HUT77469A (hu) 1998-05-28
JPH10508295A (ja) 1998-08-18
US20020155099A1 (en) 2002-10-24
DE69524238D1 (de) 2002-01-10
JP4148328B2 (ja) 2008-09-10
ATE209507T1 (de) 2001-12-15
US6680301B2 (en) 2004-01-20
NO943327D0 (no) 1994-09-08
MX9701676A (es) 1998-04-30
EP0783323B1 (en) 2001-11-28
DE69524238T2 (de) 2002-07-18
NZ509519A (en) 2004-10-29
CN1164829A (zh) 1997-11-12
EP0783323A1 (en) 1997-07-16
BRPI9508825B8 (pt) 2021-07-06
FI970983L (fi) 1997-03-07
CA2199290C (en) 2010-10-26
KR100395615B1 (ko) 2003-12-31
KR100529967B1 (ko) 2005-11-22
NO943327L (no) 1996-03-11
WO1996007432A1 (en) 1996-03-14
NO180167C (no) 1997-02-26
HK1004110A1 (en) 1998-11-20
BR9508825A (pt) 1998-01-06
CZ65897A3 (en) 1997-10-15
CN1222309C (zh) 2005-10-12
NZ293008A (en) 2001-04-27
ES2163527T3 (es) 2002-02-01
US20030134813A1 (en) 2003-07-17
AU3534795A (en) 1996-03-27
CA2199290A1 (en) 1996-03-14
PT783323E (pt) 2002-03-28
FI970983A0 (fi) 1997-03-07
FI121328B (fi) 2010-10-15
NO180167B (no) 1996-11-18
HU222984B1 (hu) 2004-01-28
BRPI9508825B1 (pt) 2020-12-22
US5876989A (en) 1999-03-02

Similar Documents

Publication Publication Date Title
KR970705415A (ko) 세포의 시토졸내로 분자를 전달시키는 방법(transfer of molecules into the cytosol of cells)
Thiel et al. Single‐Molecule Imaging of Active Mitochondrial Nitroreductases Using a Photo‐Crosslinking Fluorescent Sensor
Kosower et al. Thiol labeling with bromobimanes
Bayley et al. [8] Photoaffinity labeling
Moreno et al. Light‐Driven Proton Transfer for Cyclic and Temporal Switching of Enzymatic Nanoreactors
Paquette et al. BIOLOGICAL ACTIVITIES OF PHTHALOCYANINES—VIII. CELLULAR DISTRIBUTION INV–79 CHINESE HAMSTER CELLS AND PHOTOTOXICITY OF SELECTIVELY SULFONATED ALUMINUM PHTHALOCYANINES
Scalise et al. Photodynamic effect of metallo 5-(4-carboxyphenyl)-10, 15, 20-tris (4-methylphenyl) porphyrins in biomimetic AOT reverse micelles containing urease
Mizutani et al. An artificial receptor for dimethyl aspartate
Madhani et al. Biological activity of designed photolabile metal nitrosyls: light-dependent activation of soluble guanylate cyclase and vasorelaxant properties in rat aorta
Anderton et al. Flavin-Mediated Photocatalysis Provides a General Platform for Sulfide C–H Functionalization
Nojima et al. Water‐Rich Fluid Material Containing Orderly Condensed Proteins
Araújo et al. Azides and porphyrinoids: Synthetic approaches and applications. Part 1—Azides, Porphyrins and Corroles
RU2006130260A (ru) Система-носитель наночастиц на основе протеина для клеточно-специфического обогащения действующих лекарственных веществ
Stryer Exploring light and life
Liu et al. Chlorophyll-Inspired red-region fluorophores: building block synthesis and studies in aqueous media
Ricchelli et al. Factors influencing the distribution pattern of porphyrins in cell membranes
Klingenburg et al. Nucleophilic thioglycosylation of pentafluorophenyl-substituted porphyrinoids: Synthesis of glycosylated calix [n] phyrin and [28] hexaphyrin systems
Søgaard et al. Artificial Internalizing Receptor Affords Fast, Potent, Specific Drug Delivery to the Chemically Engineered Cells
Iida et al. Energy transfer and electron transfer of poly (ethylene glycol)-linked fluorinated porphyrin derivatives in lipid bilayers
Eldem et al. Electrophilic reactivity of cationic triarylmethane dyes towards proteins and protein-related nucleophiles
Mutti et al. Organometallic DNA–B12 Conjugates as Potential Oligonucleotide Vectors: Synthesis and Structural and Binding Studies with Human Cobalamin‐Transport Proteins
Alvarez et al. Pharmacokinetic and tumour-photosensitizing properties of methoxyphenyl porphyrin derivative
Sverdlov Yuri Anatolyevich Ovchinnikov and I. The Big is Seen from a Distance
Meeus et al. Copper‐Catalyzed Sulfimidation in Aqueous Media: a Fast, Chemoselective and Biomolecule‐Compatible Reaction
Vicente Novel reactions of porphyrin and chlorin macrocycles

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970307

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000630

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010924

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20020723

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20030226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20020723

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20010924

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20000630

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20030326

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20030226

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20030619

Appeal identifier: 2003101001159

Request date: 20030326

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20030411

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20030411

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20030326

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20021121

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20010130

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19981215

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20030619

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20030514

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20030811

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20030812

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20060728

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20070731

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20080728

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20090804

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20100812

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20110803

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20120806

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20120806

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20130801

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20130801

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20140731

Start annual number: 12

End annual number: 12

PC1801 Expiration of term